Companies › General Oncology
3 active drug programs in 30 registered trials: 17 Phase 2, 12 Phase 1, 1 Phase 3; Oncology, Hematology, Immunology, Neurology; next expected readout Dec 2028.
Open in Phaseline: competitors, likelihood bands and readouts Company report
| Drug | Target | Highest phase | Conditions | Next expected readout |
|---|---|---|---|---|
| Carmustine Glutathione reductase inhibitor | GSR | Phase 1 | Pancreatic Adenocarcinoma Metastatic; Metastatic Malignant Neoplasm in the Liver; Glioblastoma Multiforme; Non-Hodgkin Lymphoma … | Dec 2028 |
| Melphalan Alkylating agent (nitrogen mustard derivative) | UNKNOWN | Phase 1 | Pancreatic Adenocarcinoma Metastatic; Retinoblastoma; Primary Immunodeficiency (PID); Refractory and/or Relapsed Metastatic Solid Tumors … | Dec 2028 |
| Vitamin B12b (Hydroxocobalamin) Cyanocobalamin precursor; B12 vitamin cofactor supplementation | – | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Dec 2028 |
| Registry id | Drug | Phase | Conditions | Area | Expected readout |
|---|---|---|---|---|---|
| NCT01962415 | Melphalan | Phase 2 | Primary Immunodeficiency (PID) | Immunology | Nov 2026 |
| NCT00544466 | Melphalan | Phase 1 | Leukemia | Oncology | Dec 2026 |
| NCT01054196 | Melphalan | Phase 1 | Multiple Myeloma | Oncology | Dec 2026 |
| NCT01804634 | Melphalan | Phase 2 | Refractory and/or Relapsed Metastatic Solid Tumors | Oncology | Jan 2027 |
| NCT04728633 | Carmustine | Phase 2 | Metastatic Malignant Neoplasm in the Liver | Oncology | Jan 2027 |
| NCT05052957 | Carmustine | Phase 2 | Glioblastoma Multiforme | Oncology | Mar 2027 |
| NCT06313502 | Melphalan | Phase 1 | Plasma Cell Disorder | Oncology | Apr 2027 |
| NCT03118492 | Melphalan | Phase 1 | Secondary Myelofibrosis | Oncology | Apr 2027 |
| NCT04483206 | Melphalan | Phase 1 | Multiple Myeloma | Oncology | Jun 2027 |
| NCT01885689 | Melphalan | Phase 2 | Adult Acute Lymphoblastic Leukemia in Remission | Oncology | Aug 2027 |
| NCT06028828 | Melphalan | Phase 2 | Allogeneic Hematopoietic Stem Cell Transplantation | Oncology | Sep 2027 |
| NCT03125642 | Melphalan | Phase 2 | Non-Hodgkin Lymphoma | Oncology | Sep 2027 |
| NCT03125642 | Carmustine | Phase 2 | Non-Hodgkin Lymphoma | Oncology | Sep 2027 |
| NCT02605421 | Melphalan | Phase 2 | Neuroblastoma | Oncology | Oct 2027 |
| NCT03821610 | Melphalan | Phase 2 | Acute Lymphoblastic Leukemia | Oncology | Nov 2027 |
| NCT00871013 | Melphalan | Phase 2 | Myeloma | Oncology | Dec 2027 |
| NCT04799002 | Melphalan | Phase 3 | Retinoblastoma | Oncology | Dec 2027 |
| NCT04232085 | Melphalan | Phase 2 | Primary Immune Deficiency Disorder | Hematology | Dec 2027 |
| NCT05083754 | Carmustine | Phase 1 | Glioblastoma Multiforme | Oncology | Jan 2028 |
| NCT05504291 | Melphalan | Phase 2 | Bilateral Retinoblastoma | Oncology | Mar 2028 |
| NCT04150042 | Melphalan | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Oncology | Dec 2028 |
| NCT04150042 | Carmustine | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Oncology | Dec 2028 |
| NCT04222062 | Carmustine | Phase 2 | Brain Tumor - Metastatic | Oncology | Dec 2028 |
| NCT04150042 | Vitamin B12b (Hydroxocobalamin) | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Oncology | Dec 2028 |
| NCT04150042 | Vitamin B12b (Hydroxocobalamin) | Phase 1 | Pancreatic Adenocarcinoma Metastatic | Oncology | Dec 2028 |
| NCT07025824 | Melphalan | Phase 2 | AML - Acute Myeloid Leukemia | Hematology | Sep 2029 |
| NCT00716066 | Carmustine | Phase 2 | Autoimmune Disease | Neurology | Jan 2030 |
| NCT06626516 | Carmustine | Phase 1 | Metastatic Uveal Melanoma | Oncology | Oct 2030 |
| NCT07582172 | Melphalan | Phase 2 | Acute Myeloid Leukemia With Complex Karyotype | Oncology | Nov 2031 |
| NCT05508009 | Melphalan | Phase 1 | SIOD | Immunology | Oct 2032 |
Gilead Sciences Iterum Therapeutics, International Colgate Palmolive Vaxcyte Zhejiang Raygene Pharmaceuticals
Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.